PMID- 34075388
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220228
DP  - 2022 Jan 19
TI  - Circulating LIGHT (TNFSF14) and Interleukin-18 Levels in Sepsis-Induced 
      Multi-Organ Injuries.
LID - 2021.05.25.21257799 [pii]
LID - 10.1101/2021.05.25.21257799 [doi]
AB  - The novel therapeutic target cytokine LIGHT (TNFSF14) was recently shown to play 
      a major role in COVID19-induced acute respiratory distress syndrome (ARDS). This 
      study aims to investigate the associations of plasma LIGHT and another 
      potentially targetable cytokine, Interleukin-18 (IL-18), with ARDS, acute hypoxic 
      respiratory failure (AHRF) or acute kidney injury (AKI), caused by non-COVID19 
      viral or bacterial sepsis. A cohort of 280 subjects diagnosed with sepsis, 
      including 91 cases with sepsis triggered by viral infections, were investigated 
      in this cohort study. Day 0 plasma LIGHT and IL-18, as well as 59 other 
      biomarkers (cytokines, chemokines and acute-phase reactants) were measured by 
      sensitive bead immunoassay and associated with symptom severity. We observed 
      significantly increased LIGHT level in both bacterial sepsis patients 
      (P=1.80E-05) and patients with sepsis from viral infections (P=1.78E-03). In 
      bacterial sepsis, increased LIGHT level was associated with ARDS, AKI and higher 
      Apache III scores, findings also supported by correlations of LIGHT with other 
      biomarkers of organ failures. IL-18 levels were highly variable across 
      individuals, and consistently correlated with Apache III scores, mortality, and 
      AKI, in both bacterial and viral sepsis. There was no correlation between LIGHT 
      and IL-18. For the first time, we demonstrate independent effects of LIGHT and 
      IL-18 in septic organ failures. The association of plasma LIGHT with AHRF 
      suggests that targeting the pathway warrants exploration, and ongoing trials may 
      soon elucidate whether this is beneficial. Given the large variance of plasma 
      IL-18 among septic subjects, targeting this pathway requires a precision 
      application.
FAU - Qu, Hui-Qi
AU  - Qu HQ
AUID- ORCID: 0000-0001-9317-4488
FAU - Snyder, James
AU  - Snyder J
FAU - Connolly, John
AU  - Connolly J
FAU - Glessner, Joseph
AU  - Glessner J
FAU - Kao, Charlly
AU  - Kao C
FAU - Sleiman, Patrick M A
AU  - Sleiman PMA
FAU - Hakonarson, Hakon
AU  - Hakonarson H
AUID- ORCID: 0000-0003-2814-7461
LA  - eng
PT  - Preprint
DEP - 20220119
PL  - United States
TA  - medRxiv
JT  - medRxiv : the preprint server for health sciences
JID - 101767986
UIN - Biomedicines. 2022 Jan 25;10(2):. PMID: 35203474
PMC - PMC8168398
EDAT- 2021/06/03 06:00
MHDA- 2021/06/03 06:01
PMCR- 2022/01/20
CRDT- 2021/06/02 06:47
PHST- 2021/06/03 06:00 [pubmed]
PHST- 2021/06/03 06:01 [medline]
PHST- 2021/06/02 06:47 [entrez]
PHST- 2022/01/20 00:00 [pmc-release]
AID - 2021.05.25.21257799 [pii]
AID - 10.1101/2021.05.25.21257799 [doi]
PST - epublish
SO  - medRxiv [Preprint]. 2022 Jan 19:2021.05.25.21257799. doi: 
      10.1101/2021.05.25.21257799.